Rachlin Evan Lockwood, a director at Iambic Therapeutics, Inc., has reported the acquisition of stock options, allowing him to purchase 20,300 shares of the company at a price of $16 each. This transaction, which took place on October 14, 2026, highlights Lockwood's confidence in the future of Iambic Therapeutics.
Iambic Therapeutics is a company focused on developing biological products, specifically in the life sciences sector. The company is incorporated in Delaware and operates out of San Diego, California. It is listed under the Central Index Key (CIK) number 0001997038.
According to the filing, Lockwood's acquisition of stock options is a direct ownership transaction. Following this transaction, he will own 20,300 shares of Iambic Therapeutics. The options will vest on October 14, 2027, which means Lockwood will have the right to exercise these options and purchase the shares at the specified price at that time.
This acquisition may impact Iambic Therapeutics' stakeholders, including investors and employees, as it reflects Lockwood's belief in the company's potential. The biological products industry is known for its innovation and growth, and such moves by directors can influence market perceptions and employee morale.
The filing does not say what happens next.
Details of the Transaction
The stock options acquired by Lockwood are set to expire on October 14, 2036, providing a ten-year window for him to exercise these options. This long-term vesting schedule may indicate a strategic approach to aligning his interests with the company's performance over an extended period.
Lockwood's transaction is classified under the SEC Form 4 as a direct acquisition, which is significant as it reflects his personal investment in Iambic Therapeutics. As a director, his actions are closely monitored by investors, and this acquisition may serve to bolster confidence among shareholders regarding the company's future prospects.
Company Overview
Iambic Therapeutics, Inc. operates within the biological products sector, specifically focusing on non-diagnostic substances. The company is headquartered at 5627 Oberlin Drive, Suite 120, San Diego, California, and is incorporated in Delaware. Its fiscal year ends on December 31, and it is identified under the Central Index Key (CIK) number 0001997038.
The filing does not include any information about Lockwood's previous transactions or his overall ownership stake in the company prior to this acquisition.